A-Z Clinical Trials Unit

亚拉巴马至赞比亚临床试验单位（A-to-Z CTU）代表了美国大学与美国大学之间的合作。 伯明翰的亚拉巴马（UAB）和赞比亚的传染病研究中心（CIDRZ）。UAB拥有 自1990年以来，NIH一直资助进行HIV网络临床试验，并于2015年增加了 CIDRZ CRS应DAIDS的要求。在过去的6年里，我们的团队已经成功地招收了1000多名 参与者，包括45%的女性和59%的少数民族参与者，进入48个网络试验，并作出了贡献， 网络出版物175份。我们已经达到或超过了关于入学，保留， 数据管理、药房管理以及实验室设施和指标。过去的表现 A-to-Z CTU证明了我们团队为NIH资助的HIV临床研究做出贡献的准备 未来七年的网络测试在此应用程序中，我们强调A到Z CTU对艾滋病毒的承诺 具有以下具体目标的研究： 目标1.在我们的两个临床研究中心有效地招募和留住参与者参加HIV临床试验， 产生最高质量的数据，以满足HVTN，HPTN和ACTG科学的需求 网络及其各自的科学研究议程。 目标2.保持一个有凝聚力的、一体化的研究者和工作人员团队， 参与、互动、解决问题、灵活的人员配置、质量数据和样本管理，以及 监管保证目前存在，这从我们的高质量业绩记录中可以看出。 目标3：通过与网络领导层保持接触，为各自的科学议程做出贡献， 快速响应新出现的科学优先事项，包括快速扩大方案的能力- 为任何由DAIDS资助的研究网络提供有针对性的高度优先研究的具体网站。 目标4。指导一群才华横溢的年轻研究人员，他们将为持续卓越的研究奠定基础。 这一不断变化的艾滋病研究领域在国内和国际。 我们将利用我们在临床试验方面的长期经验，通过NIH为艾滋病毒研究做出贡献， 艾滋病毒临床试验网络。

The Alabama to Zambia Clinical Trials Unit (A-to-Z CTU) represents a collaboration between the University of Alabama at Birmingham (UAB) and the Centre for Infectious Diseases Research in Zambia (CIDRZ). UAB has been continuously funded to perform NIH-funded HIV network clinical trials since 1990 and in 2015 added the CIDRZ CRS at the request of DAIDS. Over the past 6 years, our team has successfully enrolled over 1000 participants, including 45% female and 59% minority participants, into 48 network trials and contributed to over 175 publications of the networks. We have met or exceeded the expectations regarding enrollment, retention, data management, pharmacy management, and laboratory facilities and metrics. The past performance of the A-to-Z CTU exemplifies the preparedness of our team to contribute to the science of the NIH-funded HIV clinical trials networks for the next seven years. In this application, we highlight the A-to-Z CTU commitment to HIV research with the following specific aims: Aim 1. Enroll and retain participants efficiently into HIV clinical trials at our two clinical research sites capable of yielding the highest quality data to meet the needs of the HVTN, the HPTN and the ACTG scientific networks and their respective scientific research agendas. Aim 2. Maintain a cohesive, integrated group of investigators and staff where communication, community engagement, interaction, problem solving, flexible staffing, quality data and sample management, and regulatory assurance currently exist as evident via our track record of high-quality performance. Aim 3. Contribute to the respective scientific agendas by remaining engaged with the network leadership to respond quickly to emerging scientific priorities, including the ability to rapidly scale-up a protocol- specific site for targeted, high-priority studies for any DAIDS-funded research network. Aim 4. Mentor a talented group of young investigators who will lay the foundation for continued excellence in this ever-changing field of HIV research domestically and internationally. We will leverage our long-standing experience in clinical trials to contribute to HIV research through the NIH- funded HIV clinical trial networks.